MARKET WIREYahoo Finance • 1d ago
Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn QuestionYahoo Finance report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
Why STOK Stock advanced +0.72% Today — RQD Quant Desk Flash
$26.48 +0.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $26.46
Stoke Therapeutics Inc. (STOK) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.70B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on STOK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is STOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Stoke Therapeutics Inc. (NASDAQ: STOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $26.48 (+0.72% 1D, market cap $1.70B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, STOK ranks #326 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does STOK compare to NUVB and QURE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STOK carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.1%. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and QURE (uniQure N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.72B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for STOK?
▼
Per STOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001623526), Stoke Therapeutics Inc. generated $184.4M in revenue (+404.5% YoY), -$6.9M in net income, and $44.9M in free cash flow against $418.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $26.46 (-0.06%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 24.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STOK)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY STOK SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)
Altman Z-Score 14.79 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 24.4% FCF Margin ($44.9M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)
Macro rate sensitivity & RSI-14 (52.3) create a -15 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$22.50+18.3% Next Q
38
Q2 (-2Q)Grade D$26.61-1.8% Next Q
41
Q3 (-1Q)Grade D$26.13+1.3% Next Q
43
CurrentGrade D$26.48-6.1% Hist 90D α
46
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a STOK Turnaround Squeeze
While STOK currently carries a cautious 46/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.19) and Max Pain ($27.80) forces dealer call-delta covering toward $42.23.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $STOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STOK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why STOK Stock advanced +0.72% Today — RQD Quant Desk Flash
Stoke Therapeutics Inc. (STOK) advanced +0.72% to $26.48, trading at 31% of its 52-week range ($20.32 – $40.22). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 31% of its 52-week range ($20.32 – $40.22) with RSI-14 at 52.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.3% around $26.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $44.9M annual free cash flow.
Live STOK Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
Stoke Therapeutics: The Market Misread A Key FDA Win (NASDAQ:STOK)Seeking Alpha report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Stoke Therapeutics, Inc. Estimates – NASDAQ:STOKTradingView report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q3 Revenue $11.3M, vs. FactSet Est of $8.2Mwww.marketscreener.com report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Stoke Therapeutics Q3 2026 Earnings Call TranscriptBenzinga report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights:GuruFocus report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMugglehead Investment Magazine • 1d ago
Stoke Therapeutics details Dravet cognition analysis after FDA meetingMugglehead Investment Magazine report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Stoke (STOK) Q3 2026 Earnings Call TranscriptDravet syndrome trial enrollment exceeded targets with zero discontinuations.
MARKET WIREYahoo • 4d ago
Stoke Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby summary of Stoke Therapeutics, Inc.'s Q3 2026 earnings call
MARKET WIREYahoo • 4d ago
Stoke Therapeutics Q3 Earnings Call HighlightsStoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulato
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STOK)
- ✓Walkthrough of STOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
STOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.53%📐 HORIZONTAL RANGE
2026-11-03O $26.35H $26.48L $26.29C $26.48VOL 1.86M
RES: $34.25SUP: $20.84SMA50: $27.19SMA200: $30.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
STOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +404.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on STOK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for STOK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STOK)
Health Care Rank #326 of 1015
⚔️ NUVB vs STOK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (STOK vs. NUVB, QURE, KLRA, ANIP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Stoke Therapeutics Inc. (STOK) ranks #326 by composite RQD confidence (46/100, grade D) and #280 by equity capitalization ($1.70B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with STOK at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STOK
ACTIVE
Stoke Therapeutics Inc. | D | 46/100 | — | — | -6.1% | +0.72% | $1.70B | Benchmark Subject |
| NUVB Nuvation Bio Inc. (Class A) | E | 19/100 | — | — | -35.0% | -3.57% | $1.67B | /nuvb-vs-stok → |
| QURE uniQure N.V. | D- | 38/100 | — | — | -35.0% | -7.49% | $1.72B | /qure-vs-stok → |
| KLRA Kailera Therapeutics Inc. | D | 45/100 | — | — | — | -5.52% | $1.67B | /klra-vs-stok → |
| ANIP ANI Pharmaceuticals Inc. | C | 63/100 | 21.5x | — | 16.0% | -1.85% | $1.65B | /anip-vs-stok → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001623526 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stoke Therapeutics Inc. (STOK) reported GAAP revenue of $184.4M (+404.5% vs. FY2024 revenue of $36.6M , and +2000.5% cumulative change since FY2023) , GAAP net income of -$6.9M, operating cash flow of $45.6M, and free cash flow of $44.9M (+151.6% YoY). On the balance sheet, STOK closed FY2025 with $418.4M in total assets against $0 in total debt (Altman Z-Score: 14.79, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $184.4M | -$6.9M | $45.6M | $44.9M | $418.4M | — |
| FY2024 (FY) | 2024-12-31 | $36.6M | -$89.0M | -$86.9M | -$87.1M | $271.6M | — |
| FY2023 (FY) | 2023-12-31 | $8.8M | -$104.7M | -$81.1M | -$81.1M | — | — |
3. STOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs STOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Stoke Therapeutics Inc. (NASDAQ: STOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $26.48 (+0.72% 1D, market cap $1.70B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, STOK ranks #326 in composite RQD confidence.
How does STOK compare to NUVB and QURE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STOK carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.1%. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and QURE (uniQure N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.72B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for STOK?
Per STOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001623526), Stoke Therapeutics Inc. generated $184.4M in revenue (+404.5% YoY), -$6.9M in net income, and $44.9M in free cash flow against $418.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is STOK trading relative to its 50-day, 200-day, and 52-week technical levels?
STOK last traded at $26.48 (+0.72% on volume of 1,404,445 shares), positioning the stock -2.61% below its 50-day simple moving average ($27.19) and -14.28% below its 200-day simple moving average ($30.89). Across its 52-week range of $20.32 to $40.22, STOK sits at the 31.0% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($24.02 to $28.94).
ROARABLE RATING BRIEF • RQD 46/100 (D)
✓ SEC XBRL & RQD VERIFIED
STOK — Stoke Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Stoke Therapeutics Inc. (STOK) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $26.48 (+0.72% 1D, market capitalization $1.70B).
- Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -6.1%, gross margin of —, operating margin of -11.2%, and free cash flow yield of 2.64%.
- Whale 13F & Options Flow (7/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 14.79, Piotroski F-Score of 6/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Stoke Therapeutics Inc. (STOK) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. — for specific product lines, customer segments, or revenue model details beyond the sector and industry classification. The profile does not describe what the company sells or to whom.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Stoke Therapeutics Inc. (STOK) reported $184.4M in annual revenue (up from $36.6M in FY2024, +404.5% YoY) and -$6.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.8M revenue, -$104.7M net income) through FY2025, STOK scaled operating cash flow to $45.6M and free cash flow to $44.9M, backed by $418.4M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.64% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $20.32 – $40.22 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— The Butterfly Supply-Chain Graph lists supply_chain as NONE, with an empty set of butterfly links and no proprietary signals. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are documented in the sources.
- Key Question #1: Can STOK sustain or expand its -11.2% operating margin and -6.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $184.4M and free cash flow of $44.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is STOK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
STOK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Stoke Therapeutics Inc. (STOK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn Question Yahoo Finance report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Stoke Therapeutics: The Market Misread A Key FDA Win (NASDAQ:STOK) Seeking Alpha report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Stoke Therapeutics, Inc. Estimates – NASDAQ:STOK TradingView report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q3 Revenue $11.3M, vs. FactSet Est of $8.2M www.marketscreener.com report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Stoke Therapeutics Q3 2026 Earnings Call Transcript Benzinga report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: GuruFocus report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago
Stoke Therapeutics details Dravet cognition analysis after FDA meeting Mugglehead Investment Magazine report covering Stoke Therapeutics Inc. (STOK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 4d ago
Stoke (STOK) Q3 2026 Earnings Call Transcript Dravet syndrome trial enrollment exceeded targets with zero discontinuations.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
STOK Bull vs. Bear Conversation Board — What's Your Call at $26.48?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STOK 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $31.29 (+19.0%)
📌 Pinned Debate Revenue grew from $8.8M in FY 2023 to $184.4M in FY 2025 while net loss narrowed to -$6.9M and FCF reached $44.9M, with a Z-Score of 14
Don't sleep on STOK's setup in Health Care. Revenue grew from $8.8M in FY 2023 to $184.4M in FY 2025 while net loss narrowed to -$6.9M and FCF reached $44.9M, with a Z-Score of 14.79 and a 6/9 Piotroski F-Score supporting the balance sheet.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (46/100) backs up the fundamental quality.
EarningsSniper 🐂 BULL
@ShortSeller_Dan Shorting a 7/20 institutional whale-flow stock at $26.29 is dangerous when funds are rotating into Health Care.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $19.72 (-25.0%)
Spot @ $26.29 ROIC of -6.1%, an RQD score of 46 with pillar scores of 5/20 on macro fit and 7/20 on both whale flow and insider conviction, and unava
I respect the product at Stoke Therapeutics Inc., but the stock at $26.29 is a different story. ROIC of -6.1%, an RQD score of 46 with pillar scores of 5/20 on macro fit and 7/20 on both whale flow and insider conviction, and unavailable valuation multiples leave the stock rated as a distribution warning.. FCF yield is 2.64% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?